Hal Bar­ron’s swan song as GSK R&D chief ends with a promise: The best is yet to come

Em­ma Walm­s­ley has one cen­tral mes­sage for to­day’s Q4 up­date: Start­ing in 2022, Glax­o­SmithK­line will be­gin a new era of growth.

The long-an­tic­i­pat­ed spin­off of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER